NO761227L - - Google Patents
Info
- Publication number
- NO761227L NO761227L NO761227A NO761227A NO761227L NO 761227 L NO761227 L NO 761227L NO 761227 A NO761227 A NO 761227A NO 761227 A NO761227 A NO 761227A NO 761227 L NO761227 L NO 761227L
- Authority
- NO
- Norway
- Prior art keywords
- triamterene
- cyclothiazide
- pharmaceutical compositions
- per
- compositions obtained
- Prior art date
Links
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims description 31
- 229960001288 triamterene Drugs 0.000 claims description 31
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 claims description 29
- 229960003176 cyclothiazide Drugs 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000011282 treatment Methods 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000001882 diuretic effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010050394 Hyperkaliuria Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000036230 kaliuresis Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000054 salidiuretic effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000036325 urinary excretion Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003337 anti-kaliuretic effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005048 flame photometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002077 kaliuretic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7511377A FR2314719A1 (fr) | 1975-04-11 | 1975-04-11 | Nouveau medicament notamment diuretique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO761227L true NO761227L (xx) | 1976-10-12 |
Family
ID=9153829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO761227A NO761227L (xx) | 1975-04-11 | 1976-04-09 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4056618A (xx) |
| JP (1) | JPS51123833A (xx) |
| BE (1) | BE840608A (xx) |
| CA (1) | CA1059913A (xx) |
| DE (1) | DE2615694B2 (xx) |
| DK (1) | DK137376A (xx) |
| ES (1) | ES446878A1 (xx) |
| FR (1) | FR2314719A1 (xx) |
| GB (1) | GB1547826A (xx) |
| GR (1) | GR60258B (xx) |
| HU (1) | HU170891B (xx) |
| IE (1) | IE44117B1 (xx) |
| IL (1) | IL49291A (xx) |
| NL (1) | NL184599C (xx) |
| NO (1) | NO761227L (xx) |
| NZ (1) | NZ180534A (xx) |
| PT (1) | PT64998B (xx) |
| ZA (1) | ZA761880B (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3305935C2 (de) * | 1983-02-21 | 1985-05-30 | Medice Chem.-Pharm. Fabrik Pütter GmbH & Co KG, 5860 Iserlohn | Kaliumneutrales Saluretikum mit antihypertensiver Wirkung |
| US4898729A (en) * | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
| US5846554A (en) * | 1993-11-15 | 1998-12-08 | Zeneca Limited | Microcapsules containing suspensions of biologically active compounds and ultraviolet protectant |
| EP2727587A1 (en) * | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3275625A (en) * | 1966-09-27 | Derivatives of |
-
1975
- 1975-04-11 FR FR7511377A patent/FR2314719A1/fr active Granted
-
1976
- 1976-03-25 IL IL49291A patent/IL49291A/xx unknown
- 1976-03-26 HU HU76RO00000885A patent/HU170891B/hu not_active IP Right Cessation
- 1976-03-29 DK DK137376A patent/DK137376A/da unknown
- 1976-03-29 ZA ZA761880A patent/ZA761880B/xx unknown
- 1976-03-31 GB GB13102/76A patent/GB1547826A/en not_active Expired
- 1976-04-06 JP JP51037878A patent/JPS51123833A/ja active Granted
- 1976-04-06 NZ NZ180534A patent/NZ180534A/xx unknown
- 1976-04-08 CA CA249,806A patent/CA1059913A/fr not_active Expired
- 1976-04-08 US US05/674,755 patent/US4056618A/en not_active Expired - Lifetime
- 1976-04-09 NO NO761227A patent/NO761227L/no unknown
- 1976-04-09 ES ES446878A patent/ES446878A1/es not_active Expired
- 1976-04-09 NL NLAANVRAGE7603767,A patent/NL184599C/xx not_active IP Right Cessation
- 1976-04-09 IE IE758/76A patent/IE44117B1/en unknown
- 1976-04-09 GR GR50511A patent/GR60258B/el unknown
- 1976-04-09 DE DE2615694A patent/DE2615694B2/de not_active Ceased
- 1976-04-09 PT PT64998A patent/PT64998B/pt unknown
- 1976-04-09 BE BE166037A patent/BE840608A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE2615694A1 (de) | 1976-10-21 |
| IL49291A0 (en) | 1976-05-31 |
| FR2314719A1 (fr) | 1977-01-14 |
| IL49291A (en) | 1979-05-31 |
| DE2615694B2 (de) | 1979-06-28 |
| HU170891B (hu) | 1977-09-28 |
| ZA761880B (en) | 1977-08-31 |
| IE44117B1 (en) | 1981-08-26 |
| PT64998B (fr) | 1978-04-03 |
| JPS51123833A (en) | 1976-10-28 |
| GR60258B (en) | 1978-04-20 |
| US4056618A (en) | 1977-11-01 |
| FR2314719B1 (xx) | 1978-10-06 |
| IE44117L (en) | 1976-10-11 |
| AU1287676A (en) | 1977-10-13 |
| PT64998A (fr) | 1976-05-01 |
| ES446878A1 (es) | 1977-11-01 |
| NL184599C (nl) | 1989-09-18 |
| DK137376A (da) | 1976-10-12 |
| CA1059913A (fr) | 1979-08-07 |
| NL7603767A (nl) | 1976-10-13 |
| GB1547826A (en) | 1979-06-27 |
| JPS6112892B2 (xx) | 1986-04-10 |
| NZ180534A (en) | 1978-04-28 |
| BE840608A (fr) | 1976-10-11 |
| NL184599B (nl) | 1989-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60005940T2 (de) | Zusammensetzung zur behandlung sexueller funktionsstörungen die phosphodiesterase-5 inhibitoren enthaltend | |
| Dresser et al. | Ipecac myopathy and cardiomyopathy. | |
| Aitio et al. | Enhanced metabolism and diminished efficacy of disopyramide by enzyme induction? | |
| Parkes | Adverse effects of antiparkinsonian drugs | |
| NO761227L (xx) | ||
| CN104069391B (zh) | 一种治疗痛风和高尿酸血症的中药组合物及其制备方法 | |
| DE3305935C2 (de) | Kaliumneutrales Saluretikum mit antihypertensiver Wirkung | |
| NO784357L (no) | Fremgangsmaate for fremstilling av et farmasoeytisk preparat | |
| JPS61167622A (ja) | 糖尿病コントロ−ル剤 | |
| JP4285997B2 (ja) | 性的機能不全を予防および治療するための医薬の製造におけるｎ−アセチル−ｄ−グルコサミンの使用 | |
| Witchitz et al. | A double-blind study in hypertensive patients of an original new compound, indapamide | |
| US4271191A (en) | Method of treating hyperuricemia and gout | |
| Fiddes et al. | Evaluation of indapamide 1.25 mg once daily in elderly patients with mild to moderate hypertension | |
| Borysiewicz et al. | Scombrotoxic atrial flutter. | |
| Singh | Clinical studies on amoebiasis and giardiasis evaluating the efficacy of kutaja (Holarrhena antidysenterica) in Entamoeba histolytica cyst passers | |
| DE2349186C2 (de) | Arzneimittel zur Verbesserung der Zellatmung, der Herzmuskelleistung und der Hirnfunktion | |
| Hart | Treatment of adrenocortical deficiency states | |
| JPS5953884B2 (ja) | 薬学的組成物 | |
| JP2548223B2 (ja) | 腎臓疾患治療剤 | |
| CN113632903B (zh) | 一种排浊美颜组合物及其制备工艺 | |
| WO1998000148A1 (de) | Arzneimittelzubereitungen, enthaltend kreatin mit mindestens einem salz von calcium, magnesium, mangan oder zink | |
| AU629520B2 (en) | A medicament | |
| Joshi et al. | Gastrointestinal actions of garlic oil | |
| Ramesh et al. | Discovery of Muscarine Leading to the Basic Understanding of Cholinergic Neurotransmission and Various Clinical Interventions | |
| JPH04210644A (ja) | 高血圧症治療剤 |